Tovorafenib
Small molecule
Evidence outlook
Approved: Glioma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signalSingle-arm, accepted for approval (FDA label)
Also approved (1)
- Ojemda is indicated as monotherapy for the treatment of patients 6 months of age and older with paediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies (for biomarkers-based patient selection, see section 4.2)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05566795 NCT05566795 · Glioma Registry: NCT05566795 | 3 | Objective response rate (ORR) of tovorafenib monotherapy versus SoC chemotherapy (Up to 60 months) 2027-06 | In progress: results expected 1 Jun 2027 | not yet graded | link ↗ |
View 1 more trial
NCT04775485 NCT04775485 · Glioma Every participant received tovorafenib; there was no randomization, no blinding and no comparison group, so the 67% response rate in the 77 patients of arm 1 cannot be compared with any control. The response was read by independent reviewers, but the study design remains uncontrolled. Registry: NCT04775485 | 2 | Arm 1: Overall response rate (Up to 48 months); Arm 2: Number of participants reporting adverse events (Up to 48 months); Arm 2: Number of participants with clinically significant changes in clinical chemistry parameters (Up to 48 months); Arm 2: Number of participants with clinically significant changes in hematology parameters (Up to 48 months); Arm 3: Overall response rate (Up to 48 months) 2027-05-31 | In progress: results expected 31 May 2027 | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Glioma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tovorafenib: this drug | Approved | Small molecule | Kinase Inhibitor | Weak signal | No reviewed efficacy summary in this indication | |
| Dabrafenib | Approved | Small molecule | BRAF V600E/V600K/V600D (also wild-type BRAF/CRAF) | not yet graded | No reviewed efficacy summary in this indication | |
| Dordaviprone | Approved | Small molecule | Mitochondrial caseinolytic protease P (ClpP), Dopamine D2 receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Temozolomide | Approved | Small molecule | DNA alkylation (O6-guanine) | Partial signal | NCT00626990: Overall survival: adjuvant temozolomide vs none, median 82.3 vs 46.9 months, hazard ratio 0.64 (95% CI 0.52 to 0.79), p<0.0001; concurrent temozolomide vs none, 66.9 vs 60.4 months, hazard ratio 0.97 (95% CI 0.73 to 1.28), p=0.76 (CT.gov posted results). | |
| Trametinib | Approved | Small molecule | MEK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Luvometinib | Phase 3 | Small molecule | MEK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Safusidenib | Phase 3 | Small molecule | Mutant IDH1 | not yet graded | No reviewed efficacy summary in this indication | |
| Abemaciclib (Verzenio) | Phase 2 | Small molecule | CDK4 and CDK6 | not yet graded | No reviewed efficacy summary in this indication | |
| Olutasidenib | Phase 2 | Small molecule | Mutant IDH1 | not yet graded | No reviewed efficacy summary in this indication | |
| Crelosidenib | Phase 1 | Small molecule | Mutant IDH1 and IDH2 | not yet graded | No reviewed efficacy summary in this indication | |
| Vebreltinib | Phase 1 | Small molecule | MET | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(8 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Tovorafenib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.